ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2764

Unhappiness Is Related to Worse Outcomes for Patients with Ankylosing Spondylitis and Increased Impairment in Daily Life Activities, Results from a Multinational Real-World Sample

Vibeke Strand1, R Alten2, Philip G. Conaghan3, Louise Huneault4, Emma Sullivan5, Stuart Blackburn5, Haijun Tian6, Kunal Gandhi6, Steffen Jugl7, Hedley Hamilton8 and Raj Mahapatra9, 1Stanford University School of Medicine, Palo Alto, CA, 2Rheumazentrum Ruhrgebiet, Herne, Germany, 3NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 4Novartis Pharma AG, Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, 5Adelphi Real World, Manchester, United Kingdom, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ, 7Novartis Pharma AG, Basel, Switzerland, 8any-3 Ltd, London, United Kingdom, 9gplus, London, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Ankylosing spondylitis (AS)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Unhappiness is Related to Worse Outcomes for Patients with Ankylosing Spondylitis and Increased Impairment in Daily Life Activities,

Results from a Multinational Real-World Sample

Background/Purpose: This study aimed to explore the relationship of self-reported happiness to disease activity and functional limitation in people with AS.

Methods: Data were from a cross-sectional sample of rheumatologists and their patients (pts) with AS in 15 countries. Physicians collected data on consecutively consulting AS pts including Physician Assessed Severity’ (PA severity) (choice of mild, moderate, severe), perceived change in control (choice of improving, stable, unstable, deteriorating) and general health (0 – 100 VAS). Pts completed forms on ratings of current activity and pain, assessments of health related quality of life (SF-36, EQ-5D) and disease activity (BASDAI). SF-36 question 9h (Q9h; mental health domain) asks “How much of the time during the past week have you been happy?”; responses of “All” or “Most” formed Happy (Group 1); responses of “A little” or “None” formed Not Happy (Group 2); “some” were excluded from the analysis. Groups 1 and 2 were compared using bivariate analysis.  SF-36 Question 3 (Q3; physical functioning domain) asks if the pts’ health limits them performing 10 daily activities. Results: 1,392 pts answered Q9h: 45.7% were assigned to Group 1 (Happy), 20.3% to Group 2 (Not Happy). Significantly more pts in Group 2 had moderate or severe disease, unstable or deteriorating AS, poorer general health status, worse pain, and more active AS (higher BASDAI) than Group 1 (Figure 1). 1,405 patients answered Q3, of whom 60%, 34% and 6% were considered by their physician to have mild, moderate and severe AS, respectively. The proportion of pts who reported “a lot” of limitation in each of the 10 activities increased with perceived severity (Figure 1). Of pts with severe AS, 47–73% were limited in undertaking normal physical activities, such as climbing several flights of stairs (moderate AS, 23–43%), and 22–43% could not perform activities requiring limited physical effort, such as carrying groceries or dressing themselves (moderate AS, 7–23%). It also shows that among the pts who are impaired ‘a lot’ for each activity, unhappiness increases with perceived disease severity.

Conclusion: Unhappiness in AS pts is associated with more severe or active disease, and many AS pts are limited in their ability to undertake everyday activities, with limitation and unhappiness  more common with more severe disease. Thus evaluating patient unhappiness via enquiry in routine consultation may help in assessing clinical severity, disease impact, and help inform treatment decisions.

   

 

Disclosure: V. Strand, AbbVie, Amgen, Anthera, AstraZeneca, Biogen Idec, Genentech/Roche, GSK, Janssen, Lilly, Pfizer, Regeneron, Sanofi, UCB, 5; R. Alten, Bristol-Myers Squibb, 2,Bristol-Myers Squibb, 8; P. G. Conaghan, AbbVie, Flexion, Eli Lilly, Novartis, Pfizer Inc, Roche, 5,AbbVie, Novartis, Roche, 8; L. Huneault, None; E. Sullivan, Adelphi Real World, 3; S. Blackburn, Adelphi Real World, 3; H. Tian, Novartis Pharmaceuticals Corporation, 3,Novartis Pharmaceuticals Corporation, 1; K. Gandhi, Novartis Pharmaceuticals Corporation, 1,Novartis Pharmaceuticals Corporation, 3; S. Jugl, Shareholder of Novartis Pharma AG, 1,Full-time employee of Novartis Pharma GA, Basel, Switzerland, 3; H. Hamilton, None; R. Mahapatra, None.

To cite this abstract in AMA style:

Strand V, Alten R, Conaghan PG, Huneault L, Sullivan E, Blackburn S, Tian H, Gandhi K, Jugl S, Hamilton H, Mahapatra R. Unhappiness Is Related to Worse Outcomes for Patients with Ankylosing Spondylitis and Increased Impairment in Daily Life Activities, Results from a Multinational Real-World Sample [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/unhappiness-is-related-to-worse-outcomes-for-patients-with-ankylosing-spondylitis-and-increased-impairment-in-daily-life-activities-results-from-a-multinational-real-world-sample/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/unhappiness-is-related-to-worse-outcomes-for-patients-with-ankylosing-spondylitis-and-increased-impairment-in-daily-life-activities-results-from-a-multinational-real-world-sample/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology